Výsledky vyhledávání - "Angiogenesis Inhibitors adverse effects"

Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial

Autoři: Gros, L. Bouattour, M. Dumont, C. a další

Zdroj: Liver international, vol. 45, no. 8, pp. e70196

Témata: Humans, Sunitinib/therapeutic use, Sunitinib/adverse effects, Sunitinib/blood, Male, Cholangiocarcinoma/drug therapy, Cholangiocarcinoma/mortality, Cholangiocarcinoma/pathology, Female, Middle Aged, Aged, Bile Duct Neoplasms/drug therapy, Bile Duct Neoplasms/mortality, Bile Duct Neoplasms/pathology, France, Angiogenesis Inhibitors/therapeutic use, Angiogenesis Inhibitors/adverse effects, Progression-Free Survival, Adult, Vascular Endothelial Growth Factor A/blood, Aged, 80 and over, Antineoplastic Agents/therapeutic use, Antineoplastic Agents/adverse effects, Choi criteria, VEGF, angiogenesis inhibitors, biliary tract cancer, tumour density

Popis souboru: application/pdf

Přístupová URL adresa: https://serval.unil.ch/resource/serval:BIB_F135E275450F.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_F135E275450F
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F135E275450F5

Aflibercept im klinischen Alltag: die AURIGA-Studie: 24-Monats-Ergebnisse der deutschen Kohorte behandlungsnaiver Patienten mit Makulaödem bei retinalem Venenverschluss unter Therapie mit intravitrealem Aflibercept

Autoři: Joachim Wachtlin Hakan Kaymak Hans Hoerauf a další

Zdroj: Die Ophthalmologie, 121(8):650-657

Témata: Intravitreal aflibercept, Aged [MeSH], Retinal vein occlusion, Real-World, Tomography, Optical Coherence [MeSH], Receptors, Vascular Endothelial Growth Factor/administration, Treatment naïve, Macular Edema/drug therapy [MeSH], Makulaödem, Originalien, Male [MeSH], Real world, Behandlungsnaiv, Visual Acuity/drug effects [MeSH], Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Recombinant Fusion Proteins/therapeutic use [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Macular edema, Intravitreal Injections [MeSH], Angiogenesis Inhibitors/administration, Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Retinal Vein Occlusion/complications [MeSH], Retinaler Venenverschluss, Intravitreales Aflibercept, Germany [MeSH], Angiogenesis Inhibitors/adverse effects [MeSH], Retinal Vein Occlusion/drug therapy [MeSH], Recombinant Fusion Proteins/adverse effects [MeSH], Angiogenesis Inhibitors/therapeutic use [MeSH], Recombinant Fusion Proteins/administration, 3. Good health

Přístupová URL adresa: https://repository.publisso.de/resource/frl:6519973

Linsenverletzungen als Komplikation bei intravitrealer Medikamenteneingabe

Autoři: Clemens, Christoph R. Alten, Florian Eter, Nicole a další

Zdroj: Die Ophthalmologie, 121(5):385-390

Témata: Eye Injuries/chemically induced [MeSH], Aged [MeSH], Intravitreale Injektion, Iatrogene Linsenverletzung, Dexamethasone/adverse effects [MeSH], Intravitreal injection, Originalien, Male [MeSH], Lens, Crystalline/drug effects [MeSH], Dexamethasone/administration, Hintere Kapselruptur, Dexamethasone/therapeutic use [MeSH], Female [MeSH], Iatrogenic Disease/prevention, Angiogenesis Inhibitors/administration, Humans [MeSH], Retrospective Studies [MeSH], Iatrogenic lens injury, Middle Aged [MeSH], Cataract, Posterior capsule rupture, Quiescent lens injury, Unbemerkte Linsenverletzung, Angiogenesis Inhibitors/adverse effects [MeSH], Lens, Crystalline/injuries [MeSH], Katarakt, Intravitreal Injections/adverse effects [MeSH]

Přístupová URL adresa: https://repository.publisso.de/resource/frl:6515417

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

Autoři: Stahl, Andreas Azuma, Noriyuki Wu, Wei-Chi a další

Zdroj: Eye (Lond)

Témata: Male, Vascular Endothelial Growth Factor A, 0301 basic medicine, Laser Coagulation, Recombinant Fusion Proteins, Infant, Newborn, Angiogenesis Inhibitors, Gestational Age, Article, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, 0302 clinical medicine, Infant, Newborn [MeSH], Angiogenesis Inhibitors/pharmacokinetics [MeSH], Female [MeSH], Infant, Premature [MeSH], 692/308/409, Intravitreal Injections [MeSH], 692/699/3161/3175, Angiogenesis Inhibitors/administration, Humans [MeSH], Vascular Endothelial Growth Factor A/antagonists, 692/700/1720, Receptors, Vascular Endothelial Growth Factor/administration, Laser Coagulation/methods [MeSH], Male [MeSH], 692/700/565/2194, 82/1, Retinopathy of Prematurity/drug therapy [MeSH], Angiogenesis Inhibitors/adverse effects [MeSH], Gestational Age [MeSH], article, Recombinant Fusion Proteins/administration, Intravitreal Injections, Humans, Retinopathy of Prematurity, Female, Infant, Premature

Popis souboru: application/pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38200320
https://hdl.handle.net/10807/304062
https://doi.org/10.1038/s41433-023-02919-9
https://repository.publisso.de/resource/frl:6518388

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

Autoři: Hoffmann, Laura Michels, Stephan Eandi, Chiara a další

Zdroj: BMC Ophthalmol
BMC Ophthalmology, Vol 24, Iss 1, Pp 1-7 (2024)
BMC ophthalmology, vol. 24, no. 1, pp. 520

Témata: Adverse event, Male, Aged, 80 and over, Vascular Endothelial Growth Factor A, Endophthalmitis, Recombinant Fusion Proteins, Anti-VEGF, High dose, Case Report, Angiogenesis Inhibitors, RE1-994, Middle Aged, Humans, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Intravitreal Injections, Female, Aged, Angiogenesis Inhibitors/adverse effects, Angiogenesis Inhibitors/administration & dosage, Endophthalmitis/diagnosis, Endophthalmitis/drug therapy, Endophthalmitis/chemically induced, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Uveitis/drug therapy, Uveitis/diagnosis, Uveitis/chemically induced, Aflibercept 8 mg, Intraocular inflammation, Uveitis, Ophthalmology, Receptors, Vascular Endothelial Growth Factor

Popis souboru: application/pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39623439
https://doaj.org/article/5440fa9b4fe644d89eb4b69c8a9973c3
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_8FE22615F6E80
https://serval.unil.ch/resource/serval:BIB_8FE22615F6E8.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_8FE22615F6E8
https://hdl.handle.net/2318/2035593
https://doi.org/10.1186/s12886-024-03788-w

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis

Autoři: Finger, Robert P. Dennis, Natalie Freitas, Rita L. a další

Zdroj: Adv Ther

Témata: Vascular Endothelial Growth Factor A, 0301 basic medicine, Recombinant Fusion Proteins, Network Meta-Analysis, Visual Acuity, Antibodies, Monoclonal, Infant, Angiogenesis Inhibitors, Review, Antibodies, Monoclonal, Humanized, Macular Degeneration/drug therapy [MeSH], Intravitreal Injections [MeSH], Neovascular age-related macular degeneration, Antibodies, Monoclonal/therapeutic use [MeSH], Humans [MeSH], nAMD, Ranibizumab/therapeutic use [MeSH], Network Meta-Analysis [MeSH], Anti-VEGF, Antibodies, Monoclonal, Humanized [MeSH], Network meta-analysis, Visual Acuity [MeSH], Infant [MeSH], Brolucizumab, Angiogenesis Inhibitors/adverse effects [MeSH], NMA, Recombinant Fusion Proteins/adverse effects [MeSH], Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Vascular Endothelial Growth Factor A/therapeutic use [MeSH], Child, Preschool [MeSH], 3. Good health, Macular Degeneration, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, 0302 clinical medicine, Child, Preschool, Ranibizumab, Intravitreal Injections, Humans

Popis souboru: pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35678996
https://repository.publisso.de/resource/frl:6485513

Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials

Autoři: Banna, Giuseppe Luigi Signori, Alessio Curioni-Fontecedro, Alessandra a další

Zdroj: European Journal of Cancer. 166:287-299

Témata: CTLA4, Mesothelioma, Angiogenesis Inhibitors / adverse effects, Mesothelioma, Malignant, Network Meta-Analysis, Antibodies, Monoclonal, Pre-treated, Randomised controlled trials, Angiogenesis Inhibitors, Antibodies, Monoclonal / therapeutic use, 3. Good health, PD1, Meta-analysis, 03 medical and health sciences, 0302 clinical medicine, Immunotherapy / methods, Systematic review, Chemotherapy, Humans, Immunotherapy, Network meta-analysis

Popis souboru: application/pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35358809
https://hdl.handle.net/11567/1078600
https://doi.org/10.1016/j.ejca.2022.02.030

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Autoři: Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa a další

Přispěvatelé: Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa a další

Zdroj: The Lancet Oncology. 23:612-624

Témata: MESH: Carcinoma, Male, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, Angiogenesis Inhibitors, Renal Cell / drug therapy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Ipilimumab, MESH: Lipase, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Tumor Microenvironment, Antineoplastic Combined Chemotherapy Protocols, MESH: Sunitinib, Sunitinib, Tumor Microenvironment, MESH: Antineoplastic Combined Chemotherapy Protocols / adverse effects, Humans, Prospective Studies, Carcinoma, Renal Cell, Protein Kinase Inhibitors, MESH: Nivolumab / adverse effects, Neoplasm Staging, MESH: Humans, MESH: Angiogenesis Inhibitors / adverse effects, MESH: Neoplasm Staging, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Lipase, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Ipilimumab, MESH: Male, MESH: Prospective Studies, 3. Good health, [SDV] Life Sciences [q-bio], Nivolumab, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Biomarkers, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, MESH: Female, MESH: Protein Kinase Inhibitors / adverse effects, Biomarkers

Popis souboru: application/pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35390339
https://hal.u-pec.fr/hal-04242379v1
https://doi.org/10.1016/s1470-2045(22)00128-0

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD

Autoři: Ramin Khoramnia Marta S. Figueroa Lars-Olof Hattenbach a další

Zdroj: Graefes Arch Clin Exp Ophthalmol

Témata: Inflammation, Retinal Vasculitis, Vascular Endothelial Growth Factor A, 0301 basic medicine, Retinal vascular occlusion, Wet Macular Degeneration/drug therapy [MeSH], Inflammation/diagnosis [MeSH], Humans [MeSH], Retinal Disorders, Retinal Vasculitis/diagnosis [MeSH], Intraocular inflammation, Uveitis/diagnosis [MeSH], Retinal vasculitis, Visual Acuity [MeSH], Brolucizumab, Angiogenesis Inhibitors/adverse effects [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Vascular Endothelial Growth Factor A [MeSH], Anti-vascular endothelial growth factor, Visual Acuity, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, 3. Good health, Uveitis, 03 medical and health sciences, 0302 clinical medicine, Wet Macular Degeneration, Humans

Popis souboru: application/pdf

Přístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00417-021-05518-0.pdf
https://pubmed.ncbi.nlm.nih.gov/34932153
https://hdl.handle.net/1887/3276498
https://repository.publisso.de/resource/frl:6450086

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors

Autoři: Moret, E. Ambresin, A. Gianniou, C. a další

Zdroj: Graefes Arch Clin Exp Ophthalmol
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, vol. 260, no. 3, pp. 1005-1014

Témata: Vascular Endothelial Growth Factor A, 0301 basic medicine, Recombinant Fusion Proteins, Angiogenesis Inhibitors, Medical Ophthalmology, 3. Good health, Bevacizumab, Drug Hypersensitivity, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, 0302 clinical medicine, Ranibizumab, Intravitreal Injections, Humans, Angiogenesis Inhibitors/adverse effects, Bevacizumab/adverse effects, Drug Hypersensitivity/diagnosis, Drug Hypersensitivity/drug therapy, Drug Hypersensitivity/etiology, Ranibizumab/adverse effects, Retrospective Studies, Aflibercept, Cutaneous adverse events, Drug hypersensitivity reaction, Intravitreal anti-VEGF

Popis souboru: application/pdf

Přístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00417-021-05353-3.pdf
https://pubmed.ncbi.nlm.nih.gov/34529134
https://www.ncbi.nlm.nih.gov/pubmed/34529134
https://link.springer.com/article/10.1007%2Fs00417-021-05353-3
https://link.springer.com/content/pdf/10.1007/s00417-021-05353-3.pdf
https://serval.unil.ch/notice/serval:BIB_C16845CB364E
https://serval.unil.ch/resource/serval:BIB_C16845CB364E.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_C16845CB364E7

Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study

Autoři: Cornelia Dunger-Baldauf Andreas Clemens Raman Tuli a další

Zdroj: Eye (Lond)

Témata: Angiogenesis Inhibitors, Article, 3. Good health, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Ranibizumab, Intravitreal Injections, Retinal Vein Occlusion, Humans, Prospective Studies, Retinal diseases, Intravitreal Injections [MeSH], Aged [MeSH], Clinical pharmacology, Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Angiogenesis Inhibitors/adverse effects [MeSH], Tomography, Optical Coherence [MeSH], Retinal Vein Occlusion/drug therapy [MeSH], Ranibizumab/adverse effects [MeSH], Tomography, Optical Coherence, Aged

Popis souboru: pdf

Přístupová URL adresa: https://www.nature.com/articles/s41433-021-01702-y.pdf
https://pubmed.ncbi.nlm.nih.gov/34326500
https://pubmed.ncbi.nlm.nih.gov/34326500/
https://www.nature.com/articles/s41433-021-01702-y
https://www.nature.com/articles/s41433-021-01702-y.pdf
https://repository.publisso.de/resource/frl:6442752

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.

Autoři: Mantel, I. Dirani, A. Zola, M. a další

Témata: Aged, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/adverse effects, Atrophy/chemically induced, Atrophy/diagnosis, Atrophy/epidemiology, Disease Progression, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Fundus Oculi, Humans, Incidence, Intravitreal Injections, Macula Lutea/drug effects, Macula Lutea/pathology, Male, Prognosis, Prospective Studies, Ranibizumab/administration & dosage, Ranibizumab/adverse effects, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Risk Factors, Switzerland/epidemiology, Tomography

Popis souboru: application/pdf

Relation: RETINA: The Journal of Retinal and Vitreous Diseases; https://iris.unil.ch/handle/iris/94790; serval:BIB_160E4E5271F0; 000480749600022

Dostupnost: https://iris.unil.ch/handle/iris/94790
https://doi.org/10.1097/IAE.0000000000002054

Thalidomide: an old drug with new clinical applications

Autoři: Laffitte, E. Revuz, J.

Témata: Adjuvants, Immunologic/adverse effects/*therapeutic use Angiogenesis Inhibitors/adverse effects/*therapeutic use Clinical Trials Humans Hypnotics and Sedatives/adverse effects/*therapeutic use Inflammation/drug therapy Neoplasms/blood supply/drug therapy Practice Guidelines Skin Diseases/drug therapy Thalidomide/adverse effects/*therapeutic use Tumor Necrosis Factor-alpha/biosynthesis

Relation: Expert Opinion on Drug Safety; https://iris.unil.ch/handle/iris/90400; serval:BIB_2E296AB06986

Dostupnost: https://iris.unil.ch/handle/iris/90400
https://doi.org/10.1517/14740338.3.1.47

Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.

Autoři: Casparis, H. Wolfensberger, T.J. Becker, M. a další

Témata: Aged, 80 and over, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/adverse effects, Anti-Bacterial Agents/therapeutic use, Antibodies, Monoclonal, Humanized/administration & dosage, Humanized/adverse effects, Aptamers, Nucleotide/administration & dosage, Nucleotide/adverse effects, Endophthalmitis/drug therapy, Endophthalmitis/epidemiology, Female, Humans, Incidence, Intravitreal Injections, Operating Rooms, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Vascular Endothelial Growth Factor/adverse effects, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Retrospective Studies, Risk Factors, Switzerland%2Fepidemiology%22">hic" UI="D013557">Switzerland/epidemiology, Vascular Endothelial Growth Factor A/antagonists & inhibitors

Relation: RETINA: The Journal of Retinal and Vitreous Diseases; https://iris.unil.ch/handle/iris/71521; serval:BIB_330CBF0B7150; 000336958700004

Dostupnost: https://iris.unil.ch/handle/iris/71521
https://doi.org/10.1097/IAE.0b013e31829f74b0

Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.

Autoři: Guenova, E. Weber, H.O. Voykov, B. a další

Témata: Angiogenesis Inhibitors/adverse effects, Antineoplastic Agents/adverse effects, Carcinoma, Renal Cell/drug therapy, Diabetic Angiopathies, Drug Eruptions/etiology, Drug Eruptions/pathology, Foot/pathology, Foot Diseases/etiology, Foot Diseases/pathology, Humans, Indoles/adverse effects, Kidney Neoplasms/drug therapy, Male, Middle Aged, Necrosis, Paresthesia/etiology, Pyrroles/adverse effects, Skin/pathology, Sunitinib

Relation: Archives of dermatology; https://iris.unil.ch/handle/iris/206529; serval:BIB_E66FD240FFA2; 000258504100038

Dostupnost: https://iris.unil.ch/handle/iris/206529
https://doi.org/10.1001/archderm.144.8.1081

Lower limbs erosions induced by sunitinib.

Autoři: Kluger, N. Chapelle, A. Jacot, W. a další

Témata: Adrenal Cortex Hormones/therapeutic use, Angiogenesis Inhibitors/adverse effects, Anti-Infective Agents, Local/therapeutic use, Carcinoma, Renal Cell/drug therapy, Renal Cell/secondary, Foot Ulcer/chemically induced, Foot Ulcer/drug therapy, Hand, Humans, Indoles/adverse effects, Kidney Neoplasms/drug therapy, Kidney Neoplasms/pathology, Male, Middle Aged, Molecular Targeted Therapy/adverse effects, Protein Kinase Inhibitors/adverse effects, Pyrroles/adverse effects, Skin Ulcer/chemically induced, Skin Ulcer/drug therapy, Treatment Outcome

Relation: Acta Dermato-Venereologica; https://iris.unil.ch/handle/iris/197569; serval:BIB_B6A3B0A06A37; 000292063200028

Dostupnost: https://iris.unil.ch/handle/iris/197569
https://doi.org/10.2340/00015555-1016

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Autoři: Konstantinidis, L. Mameletzi, E. Mantel, I. a další

Témata: Aged, 80 and over, Angiogenesis Inhibitors/adverse effects, Angiogenesis Inhibitors/therapeutic use, Angiomatosis/drug therapy, Angiomatosis/physiopathology, Antibodies, Monoclonal/adverse effects, Monoclonal/therapeutic use, Coloring Agents/diagnostic use, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Indocyanine Green/diagnostic use, Injections, Macular Degeneration/drug therapy, Macular Degeneration/physiopathology, Male, Retinal Diseases/drug therapy, Retinal Diseases/physiopathology, Retrospective Studies, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A/antagonists &, inhibitors, Visual Acuity/physiology, Vitreous Body

Popis souboru: application/pdf

Relation: Graefe's Archive for Clinical and Experimental Ophthalmology; 1435-702X[electronic]; https://iris.unil.ch/handle/iris/168601; serval:BIB_7BC299FDB2D0; 000268979200002

Dostupnost: https://iris.unil.ch/handle/iris/168601
https://doi.org/10.1007/s00417-009-1089-3

Thalidomide in patients with advanced multiple myeloma.

Autoři: Yakoub-Agha, I. Moreau, P. Leyvraz, S. a další

Přispěvatelé: Yakoub-Agha, I. Moreau, P. Leyvraz, S. a další

Témata: Agranulocytosis/chemically induced, Angiogenesis Inhibitors/adverse effects, Angiogenesis Inhibitors/therapeutic use, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Immunoglobulin A/blood, Immunoglobulin G/blood, Immunoglobulin Isotypes/blood, Immunoglobulin Light Chains/blood, Male, Multiple Myeloma/blood, Multiple Myeloma/drug therapy, Multiple Myeloma/immunology, Multiple Myeloma/pathology, Thalidomide/adverse effects, Thalidomide/therapeutic use, Time Factors, Treatment Outcome

Relation: The hematology journal; https://iris.unil.ch/handle/iris/160644; serval:BIB_CAA77BE7C76D

Dostupnost: https://iris.unil.ch/handle/iris/160644
https://doi.org/10.1038/sj.thj.6200031

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.

Autoři: Xu, C.F. Reck, B.H. Goodman, V.L. a další

Témata: Aged, Alanine Transaminase/blood, Angiogenesis Inhibitors/adverse effects, Antineoplastic Agents/adverse effects, Carcinoma, Renal Cell/drug therapy, Renal Cell/enzymology, Female, Genes, MHC Class I, MHC Class II, Genetic Markers, Histocompatibility Antigens Class I/genetics, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/enzymology, Male, Membrane Proteins/genetics, Middle Aged, Pharmacogenetics, Polymorphism, Single Nucleotide, Pyrimidines/adverse effects, Sulfonamides/adverse effects

Relation: Journal of Hepatology; https://iris.unil.ch/handle/iris/157389; serval:BIB_88E2F3B51D6F; 000291523000022

Dostupnost: https://iris.unil.ch/handle/iris/157389
https://doi.org/10.1016/j.jhep.2010.09.028

Oxygen care and treatment of retinopathy of prematurity in ocular and neurological prognosis

Přispěvatelé: Hyun Goo Kang Eun Young Choi Hyuna Cho a další

Témata: Age Factors, Angiogenesis Inhibitors / adverse effects, Angiogenesis Inhibitors / therapeutic use, Bevacizumab / adverse effects, Bevacizumab / therapeutic use, Birth Weight, Child Development, Child, Preschool, Comorbidity, Electronic Health Records, Gestational Age, Humans, Infant, Low Birth Weight, Newborn, Premature, Laser Coagulation* / adverse effects, Oxygen Inhalation Therapy* / adverse effects, Ranibizumab / adverse effects, Ranibizumab / therapeutic use, Respiration, Artificial* / adverse effects, Retinopathy of Prematurity / diagnosis, Retinopathy of Prematurity / etiology, Retinopathy of Prematurity / therapy, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors

Relation: SCIENTIFIC REPORTS; J02646; https://ir.ymlib.yonsei.ac.kr/handle/22282913/187880; T202200206

Dostupnost: https://ir.ymlib.yonsei.ac.kr/handle/22282913/187880
https://doi.org/10.1038/s41598-021-04221-8